Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:44 AM
Ignite Modification Date:
2025-12-25 @ 3:44 AM
NCT ID:
NCT00000702
Eligibility Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
* Aspirin, in modest doses.
* Ibuprofen, in modest doses.
* Maintenance antibiotic therapy posttherapy for an AIDS-defining opportunistic infection.
Concurrent Treatment:
Allowed:
* Blood transfusion if cardiovascular status is compromised.
Exclusion Criteria
* Active substance abuse.
Co-existing Condition:
Patients with the following conditions will be excluded:
* Concurrent or previous central nervous system infections or neoplasms.
* Active AIDS-defining opportunistic infection.
* Severe premorbid psychiatric illness.
* Confounding neurological disease.
* Concurrent neoplasms.
Concurrent Medication:
Excluded:
* Maintenance methadone or naltrexone.
* Acetaminophen.
* Mood- or central nervous system-altering drugs.
* Zidovudine for Pneumocystis carinii pneumonia (PCP).
* Acyclovir.
* Rifampin or derivatives.
* Drugs with antiretroviral activity.
* Experimental agents.
The following patients will be excluded from the study:
* Patients requiring ongoing therapy for an AIDS-defining opportunistic infection.
* Patients with a history of Mycobacterium avium intracellulare infection.
* Patients with a history of Pneumocystis carinii pneumonia infection.
* Patients with a daily temperature of 38 degrees C or more for 1 month.
Prior Medication:
Excluded:
* Zidovudine (AZT).
* Excluded within 14 days of study entry:
* Systemic anti-infectives.
* Excluded within 30 days of study entry:
* Immunomodulators and biologic response modifiers.
* Any investigational agent.
* Cytotoxic chemotherapy for Kaposi's sarcoma.
Prior Treatment:
Excluded:
* Radiation therapy.
Patients must demonstrate the following clinical and laboratory findings:
* No currently active AIDS-defining opportunistic infections.
* One negative blood culture for Mycobacterium avium intracellulare within 4-6 weeks prior to study entry.
* Constitutionally well without persistent fever.
* Less than 25 Kaposi's sarcoma lesions and less than 10 new lesions during the 30 days prior to study entry. Patients may have stable or indolently progressive mucocutaneous Kaposi's sarcoma.
* Characteristic clinical symptoms and signs of AIDS dementia complex.
* Abnormalities on 2 or more of 7 neuropsychological motor tests in the Neurological Screening Battery.
* Estimated premorbid IQ equal to or greater than 70 (+ or - 5), which is consistent with completion of sixth grade.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT00000702
Study Brief:
Protocol Section:
NCT00000702